991 resultados para MONTHLY REGIMEN
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Times Cited: 0 References: 0 Citation MapAbstract : Background: Chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard treatment for relapsed DLBCL. No study has compared salvage therapies and evaluated maintenance post ASCT.Methods: DLBCL CD 20+ in first relapse or pts refractory after first therapy were randomized between R ICE (rituximab, ifosfamide, etoposide, carboplatinum) or R DHAP (rituximab dexamethasone cytarabine cisplatinum). Responding patients received BEAM and ASCT then randomized between observation or maintenance with rituximab every 2 m for 1 yr (Gisselbrecht J Clin Oncol; 2010).Results: Analysis was made on 477 pts (R ICE: 243 pts; R DHAP: 234 pts): 255 relapses >12m, 213 refractory/early relapses; 306 pts had prior rituximab; secondary(s) IPI 0-1: 281 pts; s IPI 2-3:181pts. There was no difference in response rate between R ICE 63.6% and R DHAP 64.3%. There was no difference between R ICE and R DHAP at 4 yrs for EFS (26% vs 37% p=0.2) and OS (43% vs 51%, p=0.3). Factors affecting 4 yrs EFS, PFS and OS were: prior treatment with rituximab; early relapse< 12 m; s IPI 2-3. ASCT was performed in 255 pts and 242 randomized for maintenance: 122 pts rituximab (R), 120 pts observation (O). Distribution between R/O arms were respectively: median age 54 /53 yrs, Male 76/83; female 46/37; secondary IPI 0-1: 84/81; sIPI 2-3: 36/36. 89/76 relapses >12m., 33/41 refractory/early relapses. Median follow up was 44 m with 111 events. 4 yrs EFS was 52.8 % (CI 46-59) with 63% (CI 56-69) OS. There was no difference in EFS, PFS and OS between R and O arms. In multivariate analysis, sIPI2-3 significantly affected EFS, PFS, OS (p=0.0004). Women (83pts) had a better 4 yrs EFS 63% than male (159pts) 37% (p=0.01). The difference was only in the R arm (p=0.004). Gender was an independent prognostic factor in the R arm. Toxicity was mild with 12% SAE versus 4% for R /O respectively.Conclusions: There was no difference between R ICE and R DHAP and between post ASCT maintenance with R or O. Women did significantly better after ASCT with rituximab. Early relapses to upfront rituximab-based chemotherapy have a poor prognosis.
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections
Resumo:
Monthly Statistical Movement Summary for Entire Iowa Department of Corrections